휴메딕스

200670KOSDAQ의약품 제조업

63.0 / 100

Reference Date: 2026-04-13

Financial Score33.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Declined 9.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

HumeDx operates in two main business segments: the Aesthetic Division, producing fillers, botulinum toxin, cosmetics, and medical devices, and the CMO Division, specializing in specialty pharmaceuticals, osteoarthritis treatments, and raw material production. The company leverages its proprietary HI (High molecular Ideal reticulated matrix) technology to develop long-lasting fillers and high-performance cosmetics using pharmaceutical-grade HA and PDRN.

Number of Employees

377people

Average Salary

56.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

7.21Industry Average 14.808.0Point

Half of industry avg (excellent)

PBR

1.25Industry Average 1.042.5Point

Higher than industry avg (caution)

ROE

19.61Industry Average 4.427.0Point

4.4x industry avg (excellent)

Debt Ratio

1.15Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.7% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.9% (2-year basis)

ROE Trend

4.0 / 4

Avg ROE 17.6% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Neutral
[휴온스바이오파마 IPO] ③내부거래 20%대로 낮춰…자체 역량 강화
휴메딕스의 계열사인 휴온스바이오파마가 IPO를 위해 내부거래 비중을 낮추고 자체 역량을 강화하고 있다는 내용입니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 33,250Won52-week high 75,80052-week low 31,950

1-month return1.0Point

1m -9.52% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

8 totalPositive 1Neutral 7Negative 0

Positive배당락2026-04-01
Neutral정기주주총회결과2026-03-31
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral[기재정정]사업보고서 (2025.12)2026-03-20
Neutral사업보고서 (2025.12)2026-03-20